I'm a dermatologist — 3 anti-aging 'universal' skincare products I always recommend
Anti-aging skincare won't turn back the clock, but using the right products can help slow down the passage of time. Skincare aficionados often tout the benefits of wrinkle creams, plumping serums and youth-preserving eye creams, but according to Dr. Renita Ahluwalia, the lead Dermatologist at the Canadian Dermatology & Plastic Surgery Centre, a pared-back skincare regimen is oftentimes the way to go.
So many skincare products, anti-aging and otherwise, are "not backed by science," Ahluwalia tells Yahoo Canada. There is "no evidence" that they work. If you're going to spend the money on skincare, "invest in things that are backed by science and are good quality."
Instead of "doing 100 different things" and over-complicating your routine, Ahluwalia recommends three products that are "universal to everyone:" Sunscreen, vitamin C serum and retinol.
"I'm always surprised when [dermatology patients] want to try different treatments, but they're not wearing sunscreen every day." Forgoing daily sunscreen is a "very poor return" on your beauty investments, Ahluwalia says. The majority of photoaging comes from sun damage and exposure, so sunscreen is a "non-negotiable."
The average woman spends nearly $1,000 on beauty each year. But if you're not applying daily sunscreen, "you're not going to get the results" you want.
Skipping sunscreen and lying in tanning beds are some of the biggest skincare mistakes people make, Ahluwalia warns. If you want healthy skin, never leave your home without applying "at least an SPF 30."
"If you have issues with pigmentation in your skin, which a lot of us do, especially as we get older, I usually like a mineral-tinted sunscreen because the tint contains iron oxide, which is a visible light filter," she says.
La Roche-Posay's Anthelios Mineral One SPF 50+ Tinted Face Sunscreen has a 100 per cent mineral filter for high UVA-UVB broad-spectrum daily protection. It provides light-medium coverage and is enriched with hyaluronic acid and antioxidant vitamin E.
This 100 per cent reef-safe mineral sunscreen has a clean formula with 15 per cent non-nano zinc oxide that contains no chemical sunscreen actives.
Another staple in your skincare routine should be a "really good" vitamin C serum. A well-formulated vitamin C serum "can really improve your skin's ability to neutralize free radicals, so it boosts your sunscreen and protects your skin, kind of like an environmental shield," Ahluwalia says.
If you're in the market for a vitamin C serum, Ahluwalia suggests looking for those that have undergone the most studies and meet a threshold called the "Duke Parameters."
The Duke Parameters dictate that a vitamin C serum should contain pure L-ascorbic acid (vitamin C), have an acidic pH between 2.0 and 3.5, and be at a concentration of 10 to 20 per cent. Why? These parameters mean the serum will be the "most effective" and penetrate the skin the best.
Ahluwalia recommends: Vichy LiftActiv 15% Vitamin C Serum
Ahluwalia recommends: La Roche-Posay Pure Vitamin C12 Serum
Vichy's vitamin C serum is a great mid-priced option.
This dermatologist-approved serum is suitable for sensitive skin.
"I always recommend a retinol or something in the retinoid family, whether it's prescription grade or cosmeceutical," Ahluwalia tells Yahoo Canada.
"Something that suits a patient's skin type to maximize results because retinols are one of the most studied ingredients in dermatology; they do a lot of different things. They help increase cell turnover. They help with collagen stimulation. They help with fine lines and wrinkles. They can help with pigmentation."
Many medical-grade retinol products are covered by prescription drug plans, which, if you can tolerate them, is a great, more affordable option than a lot of in-store alternatives. However, if you want to avoid prescriptions, Ahluwalia recommends steering clear of derivatives and opting for "pure" retinol formulations instead.
"Neutrogena has some nice options," she says. "They have capsules and they have an overnight cream."
Ahluwalia recommends: Neutrogena Rapid Wrinkle Repair Retinol Serum Capsules
Ahluwalia recommends: Neutrogena Rapid Wrinkle Repair 0.3% Retinol Pro+ Night Cream
Each fragrance-free capsule contains a precise dose of pure retinol.
This retinol night cream targets the look of deep wrinkles and stubborn dark spots.
One of the most common blunders Ahluwalia sees in her practice is overcomplicated skincare routines.
"You want to use products that are tailored toward your skin type," she says. "Going with trends is not the right thing to do. Invest in good quality products that work and invest in procedures that work because that's going to give you long-term benefits for the skin."
In addition to skipping sunscreen and using tanning beds, Ahluwalia recommends avoiding manicures that are cured with UV light. "They're very damaging to the skin," she says.
Instead of skipping your manicure entirely, she recommends manicures that are "cured with LED light or just a regular manicure or dip nails."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
The 'father's mental load' and why men don't feel comfortable expressing it
The term "mental load" is commonly used to describe the responsibilities that women and mothers often bear for their families. But what about the mental load fathers carry? Haven Weits, 33, explored the topic in an episode of her podcast 'Haven!' with her friend Nick Mulenos, 35. 'Yes, we have things that we carry that the other partner may not carry,' he said on the May 5 episode. 'There's also an expectation among men that we handle our own stuff and we handle our own problems.' The clip, which amassed more than 53,000 views on TikTok, prompted some controversy in the comment section about the father mental load, whether it exists and why men don't feel comfortable expressing it. "Men use the same five chores as some sort of rebuttal to minimize their wives' work in the home while the majority of moms ALSO have a job," one Instagram user commented. "What many women don't get is the constant stress and fear that men are under constantly," another user commented. "There is no room for failure because if I fail, we all fail." There's no question fathers and men carry their own version of the mental load, said Dr. Mill Brown, chief medical officer at Spring Health, a mental health platform. And today's dads are more engaged and involved with their children than fathers in previous generations, research has shown. But societal pressure, a lack of male role models and a disregard for men's mental health have made it difficult for them to share their anxieties. 'Dads have been influenced by society to be tough, stoic, strong and hold these feelings in,' he said. 'Just because dads don't show their emotions as much as moms, doesn't mean that their feelings and stress do not exist in their family.' While Haven's mental load typically consists of daily tasks, her husband tends to think big-picture. Aaron Weits, 36, worries about long-term goals like where the family will live in five years, where the children will go to school and how to financially support those goals. 'It can be less tangible and sometimes because of that, it's harder to talk about,' he said. He also bears the burden of how to keep the family safe where they live in Los Angeles. He remembers his father doing the same thing and automatically assumed that role when he had children. 'Even if I'm hovering at the mall, I'm always keeping an eye on everyone,' Aaron said. 'It's not something I share, but it's almost innate. It's just a natural expression as a dad.' On top of household tasks and financial security, Mulenos said part of his mental load is how he can better support his wife and offload some of her mental stress. He also worries that expressing his mental load would inadvertently invalidate his wife's experiences and struggles. 'If they're bringing up 'Hey, I need help with what I'm carrying,' and your response is 'Look at what I'm carrying' – that can be invalidating,' he said. 'Even though that's not the intent, they don't want to push down what their wife is expressing to them.' A new age of parenting has created various pressures and challenges for both moms and dads, mental health experts said. Both parents tend to worry about income stability, financial issues, job performance and keeping track of a busy family. 'Trying to be a modern parent comes with its own pressures, especially when compared to traditional societal expectations for the role,' Brown said. Couples can share the parenting load by having a shared calendar, setting up regular family meetings to align on tasks and consistently sharing what responsibilities each partner is taking on, he said. Date nights and one-on-one time have helped Haven and Aaron be more receptive to each other's needs when sharing the responsibilities for their family. Though he wants more men to be able to effectively communicate their needs, Mulenos hopes both men and women can recognize the importance of understanding each other's mental load. 'What I want is for the conversation around the mental load – in general – to be continued and magnified,' he said. 'It's not that I want fathers to stay silent, I want them to be transparent with their feelings but I just want it to be seen as we're carrying our family forward.' Adrianna Rodriguez can be reached at adrodriguez@ This article originally appeared on USA TODAY: Father's Day and what to know about the male 'mental load'
Yahoo
28 minutes ago
- Yahoo
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, GoodRx Holdings, Inc. (NASDAQ:GDRX) announced launching a new subscription service focused on erectile dysfunction (ED) treatment. The new service aims to innovate access to ED care by addressing common barriers such as high costs, social stigma, long wait times, and inconvenience. The key features of GoodRx Holdings, Inc.'s (NASDAQ:GDRX) new subscription service include an All-in-One Solution through which customers can book virtual consultations, get access to FDA-approved medicines, and also get discreet home deliveries. The subscription starts as low as $18 per month, with the final cost depending on the prescribed medication. We recognize that many men delay or entirely avoid treatment for ED due to stigma, costs, and the inconvenience of traditional healthcare pathways,' said Katelyn Pelak, VP and Head of Product at GoodRx Holdings, Inc. (NASDAQ:GDRX). A pharmacist assisting elderly customers with their GoodRX codes at a local pharmacy. Moreover, the company also released its latest study on ED, revealing nearly 1 in 3 men in the United States report difficulties with erections, but fewer than 14% use any treatment, largely due to insurance coverage gaps and social stigma. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading US healthcare company that helps consumers save money on prescription medications by providing free access to drug price comparisons, digital coupons, and discounts at over 70,000 pharmacies nationwide. The company operates through a mobile app and website where users can get medications, access telemedicine services to consult doctors online and receive prescriptions without insurance. It is one of the best small-cap growth stocks to buy according to analysts. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
1 Growth Stock Down 9% to Buy Right Now
Eli Lilly's share price is down about 6.4% over the past year. The pharmaceutical giant's weight-loss drugs continue to drive fast revenue and earnings growth. 10 stocks we like better than Eli Lilly › Not many companies that have been around since the late 1800s can claim that they're growth companies. But Eli Lilly (NYSE: LLY) can. However, even growth stocks with long and impressive track records can see their share prices take a breather. Eli Lilly's stock is down about 6.4% over the last year through June 12. Some may worry about such a drop, but I don't believe that's a warning sign for investors. Rather, investors should think of this dip as a buying opportunity. Eli Lilly has two weight-loss drugs on the market, Mounjaro (which also treats type 2 diabetes) and Zepbound. Both can now be classified as blockbuster drugs (which have over $1 billion in annual sales). Demand for the products shows no signs of slowing. First-quarter Mounjaro sales more than doubled year over year from $1.8 billion to $3.8 billion, with management also noting the product's expansion into new geographic markets. Zepbound's sales more than quadrupled from $517.4 million to $2.3 billion. Finding a more convenient way of taking this medication could spur additional demand. Currently, patients inject themselves weekly with the drugs, which has been a deterrent for some wanting to obtain prescriptions. In April, Eli Lilly management announced a successful phase 3 trial of a daily oral treatment for type 2 diabetes and weight loss. The company expects to submit the drug for approval later this year (weight loss) and in 2026 (diabetes). The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth. With a large and growing market, and the entry of a product that will make it more convenient to take the treatment, that growth should prove sustainable for a long period. Eli Lilly has already been taking market share from chief rival Novo Nordisk (NYSE: NVO). Novo Nordisk has been struggling, and its new treatment failed to meet expectations. Meanwhile, Eli Lilly's existing weight-loss drugs appear to produce better results. In fact, Eli Lilly had difficulty meeting skyrocketing demand in the past. That's a nice problem to have. Eli Lilly's total first-quarter revenue grew 45% year over year to $12.7 billion, and its diluted earnings per share (EPS) under generally accepted accounting principles (GAAP) was $3.06, 23% higher. Management expects this year's EPS to come in at $20.17 to $21.67. While it reduced its guidance from $22.05 to $23.55, the updated figures are still a tremendous increase from the $11.71 a share Eli Lilly earned in 2024. You can't call Eli Lilly shares a bargain based on the stock's trailing price-to-earnings (P/E) ratio. The shares trade at a P/E of 63 compared to the S&P 500 index's 29. Still, a year ago, when the stock price was higher, the P/E ratio stood at 125. Of course, earnings have been growing rapidly. Based on analyst estimates for the next year, Eli Lilly's stock has a forward P/E of 36. Hence, it seems the above-average valuation is justified based on growth expectations. The fast top-line and bottom-line pace doesn't seem likely to subside given Eli Lilly's leadership and potential new products in the fast-growing weight loss category. That presents a good opportunity for growth-seeking investors, and it's why I'd use the stock dip as a buying opportunity. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Growth Stock Down 9% to Buy Right Now was originally published by The Motley Fool